Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation component have been newly developed and tested in large clinical trials. Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction. Recently, large randomized clinical trials and meta-analyses have been published to show the efficacy and safety of the new oral anticoagulants compared with warfarin. Based on the results from recent clinical trials, we revised recommendations to apply optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack.
Abstract
Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation component have been newly developed and tested in large clinical trials. Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction. Recently, large randomized clinical trials and meta-analyses have been published to show the efficacy and safety of the new oral anticoagulants compared with warfarin. Based on the results from recent clinical trials, we revised recommendations to apply optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack.
참고문헌 (26)
- Jung KH, "Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke).", Circ Cardiovasc Qual Outcomes, pp.327~334 (2012)
- Kim BJ, "Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry", Int J Stroke, 9, pp.514~518 (2014)
- Go AS, "Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study", JAMA, 285, pp.2370~2375 (2001)
- Camm AJ, "2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association", Eur Heart J, 33, pp.2719~2747 (2012)
- January CT, "2014 AHA", ACC, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, pp.Circulation, 2014[DOI]
- Kernan WN, "Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack : a Guideline for Healthcare Professionals From the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
- EAFT (European Atrial Fibrillation Trial) Study Group, "Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke", Lancet, 342, pp.1255~1262 (1993), EAFT (European atrial fibrillation trial) study group
- Atrial Fibrillation Investigators, "Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials", Arch Intern Med, 154, pp.1449~1457 (1994)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Connolly SJ, "The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study", Circulation, 128, pp.237~243 (2013)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.8838~8891 (2011)
- Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Diener HC, "Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke : a subgroup analysis of the RE-LY trial", Lancet Neurol, 9, pp.1157~1163 (2010)
- Hankey GJ, "Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack : a subgroup analysis of ROCKET AF", Lancet Neurol, 11, pp.315~322 (2012)
- Diener HC, "Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial", Lancet Neurol, 11, pp.2252~2231 (2012)
- Easton JD, "Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a subgroup analysis of the ARISTOTLE trial", Lancet Neurol, 11, pp.503~511 (2012)
- Hori M, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation", Stroke, 44, pp.1891~1896 (2013)
- Ntaios G, "Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials", Stroke, 43, pp.3298~3304 (2012)
- Miller CS, "Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation", Am J Cardiol, 110, pp.453~460 (2012)
- Dentali F, "Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature", Circulation, 126, pp.2381~2391 (2012)
- Chatterjee S, "New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation", JAMA Neurol, 70, pp.1486~1490 (2013)
- Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- ACTIVE Investigators, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation", N Engl J Med, 360, pp.2066~2078 (2009)